Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Amgen (AMGN – Research Report) today. The company’s shares closed ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion ...

Srikripa Devarakonda; Analyst; Truist Securities, Inc. Good afternoon and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia and I will facilitate the audio portion of ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia trials, which the firm sees as a negative for AbbVie and ...

"ABBV's pain is BMY's gain," Truist Securities analyst Srikripa Devarakonda said in a note released Tuesday. "We see this as a negative for AbbVie (ABBV, Buy) and a positive for Bristol (BMY ...

On Nov. 5, Srikripa Devarakonda from Truist Financial maintained a “Buy” rating on Eli Lilly, with a price target of $1,029, which indicates a 23.7% upside from the current levels.

Operator? Operator: Thank you. [Operator Instructions]. Our first question comes from Srikripa Devarakonda Truist Securities. Your line is open. Srikripa Devarakonda: Hey, guys. Thank you so much ...

Thanks for taking my questions. Operator: Thank you. The next question comes from Srikripa Devarakonda with Truist. You may proceed. Srikripa Devarakonda: Hey, guys. Thank you so much for taking ...